Andrx Generic Diltiazem Will Launch After Hoechst Patent Suit Settlement
Executive Summary
Andrx will launch a reformulated once-daily diltiazem product following the resolution of a patent suit with Cardizem CD manufacturer Hoechst Marion Roussel.
You may also be interested in...
Andrx Asks FDA To Reconsider Petition To Block Biovail Diltiazem ER Generic
Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.
Andrx Asks FDA To Reconsider Petition To Block Biovail Diltiazem ER Generic
Andrx is petitioning FDA to reconsider its denial of the firm's previous citizen's petition in an effort to prevent market entry of Biovail's generic version of Hoechst Marion Roussel's Cardizem CD after expiration of Andrx' exclusivity Dec. 19.
Purepac Challenges Andrx Cardia XT Exclusivity On Reformulation Grounds
A first-to-file ANDA applicant should lose its eligibility for 180-day exclusivity if it makes major changes to the application at a later date, Purepac asserts in a petition to FDA requesting that Andrx be stripped of its exclusivity for generic sustained-release diltiazem, equivalent to Hoechst Marion Roussel's Cardizem CD.